Targeted covalent inhibitors (TCIs) have witnessed a
significant
resurgence in recent years, particularly in the kinase drug discovery
field for treating diverse clinical indications. The inhibition of
Bruton’s tyrosine kinase (BTK) for treating B-cell cancers
is a classic example where TCIs such as ibrutinib have had breakthroughs
in targeted therapy. However, selectivity remains challenging, and
the emergence of resistance mutations is a critical concern for clinical
efficacy. Computational methods that can accurately predict the impact
of mutations on inhibitor binding affinity could prove helpful in
informing targeted approachesproviding insights into drug
resistance mechanisms. In addition, such systems could help guide
the systematic evaluation and impact of mutations in disease models
for optimal experimental design. Here, we have employed in silico
physics-based methods to understand the effects of mutations on the
binding affinity and conformational dynamics of select TCIs of BTK.
The TCIs studied include ibrutinib, acalabrutinib, and zanubrutiniball
of which are FDA-approved drugs for treating multiple forms of leukemia
and lymphoma. Our results offer useful molecular insights into the
structural determinants, thermodynamics, and conformational energies
that impact ligand binding for this biological target of clinical
relevance.